Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | HNF4A | P41235 | 1/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28194187 | 1.00 | TRPA1 (0.59) | TRPA1PTPN1TTRALOX5PTGS1 | |
| SCHEMBL308225 | 1.00 | TRPA1 (0.59) | TRPA1PTPN1TTRALOX5PTGS1 | |
| Resveratrol SCHEMBL27943459 | 0.87 | PTPN1 (0.61) | TRPA1PTPN1TTRALOX5PTGS1 | |
| SCHEMBL27677458 | 0.82 | PTPN1 (0.76) | TRPA1PTPN1TTRALOX5PTGS1 | |
| SCHEMBL21686 | 0.82 | TRPA1 (0.61) | TRPA1PTPN1TTRALOX5PTGS1 | |
| SCHEMBL9742095 | 0.82 | TRPA1 (0.61) | TRPA1PTPN1TTRALOX5PTGS1 | |
| SCHEMBL30728934 | 0.82 | TRPA1 (0.61) | TRPA1PTPN1TTRALOX5PTGS1 | |
| SCHEMBL1982134 | 0.81 | TTR (0.61) | TRPA1PTPN1TTRALOX5PTGS1 | |
| SCHEMBL3681557 | 0.81 | TTR (0.61) | TRPA1PTPN1TTRALOX5PTGS1 | |
| SCHEMBL13339166 | 0.81 | TRPA1 (0.65) | TRPA1PTPN1TTRALOX5PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109991340-B | Spectrum effect relationship-based quality detection method for radix polygoni multiflori preparata | 无限极（中国）有限公司 | 2022-03-29 | — | — | CN | claimed |
| CN-112004776-A | Carbon nanotube dispersion and method for producing same | LG化学株式会社 | 2020-11-27 | — | — | CN | claimed |
| CN-110662532-A | Deformable Nanoscale Vehicles (DNVS) for cross-blood brain barrier, transmucosal and transdermal drug delivery | 加利福尼亚大学董事会 | 2020-01-07 | — | — | CN | claimed |
| CN-107427437-A | Including apply comprising（E）The purposes for preventing or handling the canescent method of hair and the plant extracts of the plant extracts of the O glucosides of 2,3,5,4 ' tetrahydroxy Stilbene 2 | 莱雅公司 | 2017-12-01 | — | — | CN | claimed |
| CN-1262269-C | Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of parkinson's disease | PORTELA & CA SA (PT) | 2006-07-05 | — | — | CN | claimed |
| CN-1429109-A | Compositions comprising blockers of L-DOPA renal cell transfer for treatment of Parkinson's disease | PORTELA & CA SA (PT) | 2003-07-09 | — | — | CN | claimed |
| CN-109991340-B | Spectrum effect relationship-based quality detection method for radix polygoni multiflori preparata | 无限极（中国）有限公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-113244399-A | Compositions and methods utilizing tyrosine kinase inhibitors | 耶鲁大学 | 2021-08-13 | — | — | CN | disclosed |
| CN-107530298-B | Compositions and methods utilizing tyrosine kinase inhibitors | 耶鲁大学 | 2021-06-04 | — | — | CN | disclosed |
| CN-105682679-B | Vectors for expression of prostate-associated antigens | 辉瑞公司 | 2020-12-08 | — | — | CN | disclosed |
| US-10849861-B2 | Pharmaceutical compound for treating colorectal cancer | EVEREST PHARM. INDUSTRIAL CO., LTD. (TW) | 2020-12-01 | — | — | US | disclosed |
| US-20200262991-A1 | Method for Tuning Topology of Polymer Particles | UNIVERSITY OF SOUTH CAROLINA | 2020-08-20 | — | — | US | disclosed |
| CN-110914258-A | NLRP3 modulators | 先天肿瘤免疫公司 | 2020-03-24 | — | — | CN | disclosed |
| CN-102316878-A | Glycolipid mixture obtained from Oscillatoria planktonic cyanobacteria of the genus Sphingomonas with anti-inflammatory activity | Bluegreen Biotech SRL | 2012-01-11 | — | — | CN | disclosed |
| CN-101257897-A | Methods and related compositions for treating or preventing obesity, insulin resistance disorders and mitochondria-related disorders | SIRTRIS PHARMACEUTICALS INC (US) | 2008-09-03 | — | — | CN | disclosed |
| CN-101247793-A | Compositions for treating or preventing obesity and insulin resistance disorders | GEN HOSPITAL CORP (US) | 2008-08-20 | — | — | CN | disclosed |
| CN-101209231-A | Cosmetic composition containing piceatannol and vitamin a compound | ALOYONE NIPPON CO LTD (JP) | 2008-07-02 | — | — | CN | disclosed |
| CN-1262269-C | Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of parkinson's disease | PORTELA & CA SA (PT) | 2006-07-05 | — | — | CN | disclosed |
| US-6506395-B2 | Method of attracting wildlife using hedge apple extract | LILLIG JAMES (US) | 2003-01-14 | — | — | US | disclosed |
| US-20020132020-A1 | Method of attracting wildlife using hedge apple extract | LILLIG JAMES (US) | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262991-A1 | Method for Tuning Topology of Polymer Particles | SPOP, CETP, AUP1 | TRPA1 4786/4885PTPN1 4255/4885TTR 320/4885 |
| US-10849861-B2 | Pharmaceutical compound for treating colorectal cancer | APC, GPBAR1, CYP7A1 | TRPA1 2012/4885PTPN1 1224/4885TTR 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.